Featured Research

from universities, journals, and other organizations

Epilepsy Drug Valproate Used During Pregnancy Linked To Lower IQ in Children, According To Study

Date:
May 9, 2007
Source:
American Academy of Neurology
Summary:
Children of women who took the epilepsy drug valproate during pregnancy appear to be at a greater risk for lower IQ, according to recent research. The study looked at IQ test results for 187 two-year-old children of mothers who took the epilepsy drugs carbamazepine, lamotrigine, phenytoin, or valproate during pregnancy.

Children of women who took the epilepsy drug valproate during pregnancy appear to be at a greater risk for lower IQ, according to recent research. The study looked at IQ test results for 187 two-year-old children of mothers who took the epilepsy drugs carbamazepine, lamotrigine, phenytoin, or valproate during pregnancy.

According to the study, 24 percent of the children of mothers who took valproate showed an IQ in the mental retardation range, compared to 12 percent for carbamazepine, nine percent for lamotrigine, and 12 percent for phenytoin. On an IQ test, children whose mothers took carbamazepine scored an average of 93 points, compared to 93 for those who took phenytoin, 96 for lamotrigine, and 84 for valproate. The scores were adjusted to account for the mother's IQ and the drug dosage.

The study also found that children with higher levels of valproate in their blood had lower IQ scores.

"Further studies are needed to confirm these findings, examine IQ at older ages, and to determine the risks for other epilepsy drugs," said study author Kimford Meador, MD, of the University of Florida in Gainesville, FL, and Fellow of the American Academy of Neurology. "However, our findings are consistent with other studies, which have shown valproate poses an increased risk for fetal death and birth defects, and have suggested the drug may harm cognitive development."

The study also found children's IQ was related to their mother's IQ for every epilepsy drug except valproate.

Meador is recommending doctors talk with their patients about the risks associated with valproate. "Although valproate remains an important treatment option in women who aren't able to use other epilepsy drugs, valproate should not be used as the drug of first choice for women of child bearing potential, and when used, its dosage should be limited if possible," said Meador.

The study was supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health.This research was presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 -- May 5, 2007.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "Epilepsy Drug Valproate Used During Pregnancy Linked To Lower IQ in Children, According To Study." ScienceDaily. ScienceDaily, 9 May 2007. <www.sciencedaily.com/releases/2007/05/070503135424.htm>.
American Academy of Neurology. (2007, May 9). Epilepsy Drug Valproate Used During Pregnancy Linked To Lower IQ in Children, According To Study. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/05/070503135424.htm
American Academy of Neurology. "Epilepsy Drug Valproate Used During Pregnancy Linked To Lower IQ in Children, According To Study." ScienceDaily. www.sciencedaily.com/releases/2007/05/070503135424.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins